Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.
about
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TBRecent developments in treatment of latent tuberculosis infectionWeekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contactsUpdates on the risk factors for latent tuberculosis reactivation and their managementsTuberculosis, nontuberculous lung infection, pleural disorders, pulmonary function, respiratory muscles, occupational lung disease, pulmonary infections, and social issues in AJRCCM in 2004Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infectionCompletion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinicTuberculosis screening of travelers to higher-incidence countries: a cost-effectiveness analysisAdverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak.Risk factors for treatment default in close contacts with latent tuberculous infection.Observational study of QuantiFERON®-TB gold in-tube assay in tuberculosis contacts in a low incidence area.New approaches in the diagnosis and treatment of latent tuberculosis infectionGeographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study.Antituberculosis drug-induced hepatotoxicity in childrenA systematic review of economic evaluations of chemoprophylaxis for tuberculosis.Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherenceInitiation and completion rates for latent tuberculosis infection treatment: a systematic review.Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review.Isoniazid preventive treatment in children in two districts of South India: does practice follow policy?Treatment of latent tuberculosis infection in HIV: shorter or longer?Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analysesTreatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial.Antituberculosis drugs and hepatotoxicity.Is Universal Screening Necessary? Incidence of Tuberculosis among Tibetan Refugees Arriving in Calgary, Alberta.Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.A guide to the management of tuberculosis in patients with chronic liver disease.Promoting adherence to treatment for latent TB infection through mobile phone text messaging: study protocol for a pilot randomized controlled trialCurrent management options for latent tuberculosis: a review.Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection.Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA.Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada.Adequacy of initiating TNF antagonists within 3 weeks of starting latent tuberculosis infection treatment in patients with immune-mediated inflammatory diseases.Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.Impact of Routine Quantiferon Testing on Latent Tuberculosis Diagnosis and Treatment in Refugees in Multnomah County, Oregon, November 2009-October 2012.A comparative effectiveness analysis of treatment for latent tuberculosis infection using multilevel selection models.Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.Management of Latent Tuberculosis Infection among Healthcare Workers: 10-year Experience at a Single Center.
P2860
Q24201325-65A7910D-0F30-44F6-8AFB-B49CB6698108Q24630473-CD915B6B-3D14-4F41-8401-DF1FA94695D1Q24650581-F96432D7-794F-4E88-8FE1-0BAAB0B4D556Q28073158-CEB6EE51-E13A-4EAF-8063-A57679547E1AQ28238675-E241FF6A-B37C-4C6B-BA97-48BD4D219A11Q28479103-E5D543D9-5E29-460B-9FAB-3760E8C5C29BQ28484855-47C75A4E-136A-4336-8231-44F0B82A8EF9Q33340828-293388ED-EE12-4BFB-B5AC-BB39C3E8CFC8Q33396678-847218ED-9643-4376-92C2-1A16309E35B9Q33768706-E35C97E2-5DB4-4A35-AAFE-DED72983AFA5Q34399197-E091229A-3F6F-41CB-A97A-CFA34B8D2975Q34419185-A3F1C327-D063-4FCE-9767-0C05A515B1F6Q34441057-8F61525E-082A-4ECD-9399-462A45E1CE4DQ35096954-E00159FF-A244-40BA-A8EF-D4E4800798B6Q35503563-232F7320-A098-43F5-A95D-E3A7F122CD7CQ35954014-7507687C-AA7C-4435-868E-723DC2E18BC9Q36019231-CCB1D3BA-DE4A-4B06-991D-B48EAE038175Q36042709-246E0D34-6E5F-49CF-AFF6-29FDEEFB11B2Q36108326-64AE687E-AF39-4B7D-8F66-0F1EFF86329BQ36137225-79CAAE8E-20C5-421F-AC90-7BF0DB48B256Q36343641-FCAF4CBA-A4DA-4A30-B982-D8271DBA1B9AQ36511908-C1F4791C-693B-40F8-8037-E2C69B976357Q36568337-E30A1FE2-D67C-4729-87CF-CF64B3510A04Q36628708-1A51EE76-0C12-4089-8D0A-D340C8CD0296Q37581105-5641BD0F-ABB1-43F5-8294-C7AC03F3A8A2Q37613267-5A6B7002-BE7E-4241-B109-D31FE69BC6ABQ37613934-5A4E81CB-B70E-46BB-AF96-E29AB3619628Q37695016-3365BA18-38A5-4F36-82DC-59391F727C3BQ38066198-2315B6C6-74AE-4839-8650-556F7730836AQ38661516-F7EACFF2-0CFC-40C0-95E5-C6AE0F73C63EQ38671667-389ABE5D-D53D-4966-B246-D94B1205A5EBQ38791152-94B8A43E-2CD4-4B5C-8DF3-0A713DF42CFEQ39149434-49498111-6881-4523-955C-B8A700005FE0Q40764520-5C5B82C8-3D9A-4AB1-8240-9D2E017B4561Q40871118-A0ADCF58-75EC-4FD0-B25A-41DC2919F46AQ40878500-6EF584F3-A8E3-4936-B8B6-2AD414DBD6DFQ41200579-A3B22F00-AC0B-4F63-8A65-2285F8193DCCQ41238712-5A2E5C7D-5662-4FCA-8B01-470977996A70Q41657767-0CF0E086-FC4F-49A4-876E-F4C6D9718628Q41987069-4C97D09E-E1F9-4634-A1EC-E89F7E4E7D61
P2860
Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Treatment completion and costs ...... versus isoniazid for 9 months.
@en
Treatment completion and costs ...... versus isoniazid for 9 months.
@nl
type
label
Treatment completion and costs ...... versus isoniazid for 9 months.
@en
Treatment completion and costs ...... versus isoniazid for 9 months.
@nl
prefLabel
Treatment completion and costs ...... versus isoniazid for 9 months.
@en
Treatment completion and costs ...... versus isoniazid for 9 months.
@nl
P2093
P2860
P1476
Treatment completion and costs ...... versus isoniazid for 9 months.
@en
P2093
Barry Rabinovitch
Kevin Schwartzman
Marie-Josée Dion
Paul Brassard
Sharyn Mannix
P2860
P304
P356
10.1164/RCCM.200404-478OC
P407
P50
P577
2004-06-01T00:00:00Z